Table 1.
Baseline characteristics of the study population before propensity score matching
| Variable | LAM group (n=155) |
ADV group (n=46) |
Standardized difference (%) | P-value |
|---|---|---|---|---|
| Age, year | 48.6±9.8 | 49.8±10.5 | 11.5 | 0.472 |
| Gender, male/female (%) | 145 (93.5)/10 (6.5) | 40 (87.0)/6 (13.0) | 19.4 | 0.254 |
| HBV-DNA (log10 IU/mL) | 5.3 (2.7–9.3) | 4.7 (2.7–6.7) | 91.5 | <0.001 |
| HBeAg, +/− (%) | 28 (18.1)/127 (81.9) | 4 (8.7)/42 (91.3) | 32.9 | 0.127 |
| Total bilirubin (μmol/L) | 13.8±7.4 | 13.9±7.0 | 1.2 | 0.944 |
| Albumin (g/L) | 40.2±4.4 | 41.4±4.2 | 28.3 | 0.11 |
| Alanine aminotransferase (IU/L) | 41.0 (8.0–504.0) | 34.5 (5.0–118.0) | 42.9 | 0.065 |
| Prothrombin time (s) | 12.9±1.4 | 12.9±1.2 | 1.0 | 0.96 |
| α-Fetoprotein, ≥400 ng/mL/<400 ng/mL (%) | 46 (29.7)/109 (70.3) | 13 (28.3)/33 (71.7) | 3.1 | 0.853 |
| Liver cirrhosis, present/absent (%) | 134 (86.5)/21 (13.5) | 38 (82.6)/8 (17.4) | 10.0 | 0.515 |
| Gastroesophageal varices, present/absent (%) | 27 (17.4)/128 (82.6) | 7 (15.2)/39 (84.8) | 6.1 | 0.726 |
| Diabetes mellitus, present/absent (%) | 10 (6.5)/145 (93.5) | 6 (13.0)/40 (87.0) | 19.4 | 0.254 |
| Tumor size (cm) | 5.0 (0.8–18.0) | 4.0 (2.0–10.2) | 54.1 | 0.102 |
| Satellite nodule, present/absent (%) | 32 (20.6)/123 (79.4) | 18 (39.1)/28 (60.9) | 37.5 | 0.011 |
| Microvascular infiltration, present/absent (%) | 19 (12.3)/136 (87.7) | 7 (15.2)/39 (84.8) | 8.1 | 0.599 |
Note: Variables are expressed as mean ± standard deviation, as median (range), or as n (%).
Abbreviations: ADV, adefovir dipivoxil; HBeAg, hepatitis B e antigen; LAM, lamivudine; s, seconds; HBV, hepatitis B virus; +/−, positive/negative.